Estados Unidos · Bolsa y Finanzas · Investor's Business Daily

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Publicado por Investor's Business Daily · Estados Unidos hace 12 h

Eli Lilly (LLY) already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market. The new contender, EloraTZP, helped patients with type 2…

Leer el artículo completo en Investor's Business Daily Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.investors.com)

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

También te puede interesar

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Compartir

También te puede interesar

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules